AstraZeneca chief executive Pascal Soriot will leave CSL’s board just months after being appointed over fears of a potential future conflict of interest between the two biotechnology giants.
Based in Boston, Alexion develops treatments for rare diseases including in the blood and heart conditions, where CSL is a major player. Mr Soriot was not set to be directly involved in discussions about the AstraZeneca vaccine production and it was planned he would abstain from board issues where there was a potential conflict of interest.
Too late insider trading information already used
Resumimos esta notícia para que você possa lê-la rapidamente. Se você se interessou pela notícia, pode ler o texto completo aqui. Consulte Mais informação: